Predictors of long-term durable response in de novo HER2-positive metastatic breast cancer and the real-world treatment experience at two institutions

被引：0
|
作者：
Claire E. P. Smith
Paul K. Marcom
Zahi Mitri
Naomi Y. Ko
机构：
[1] Boston University School of Medicine,Duke Cancer Center
[2] Boston Medical Center,undefined
[3] Duke University Hospital,undefined
[4] Oregon Health and Science University,undefined
来源：
Breast Cancer Research and Treatment | 2022年 / 196卷
关键词：
Breast Cancer; HER2; Trastuzumab; Neoplasm metastasis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：215 / 220
页数：5
相关论文
共 50 条
  • [31] A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
    Jin, N.
    Yin, Y.
    Li, W.
    Huang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S1492 - S1492
  • [32] Durable complete response following chemotherapy and trastuzumab for metastatic HER2-positive breast cancer
    Gullo, G.
    Zuradelli, M.
    Sclafani, F.
    Santoro, A.
    Crown, J.
    ANNALS OF ONCOLOGY, 2012, 23 (08) : 2204 - 2205
  • [33] Real-world outcomes associated with pyrotinib-based therapy for HER2-positive metastatic breast cancer
    Hao, L.
    Chen, J.
    Chen, M.
    Han, X.
    Pan, Y.
    ANNALS OF ONCOLOGY, 2021, 32 : S489 - S489
  • [34] Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study
    Gui, Xinyu
    Li, Huiping
    Yan, Ying
    Zhang, Ruyan
    ONCOLOGY LETTERS, 2020, 20 (06)
  • [35] Long-term trastuzumab treatment in HER2 positive metastatic breast cancer
    Calamac, M.
    Minic, I.
    Tomasevic, Z.
    Oblakovic-Babic, J.
    Serovic, K.
    Djurmez, O.
    Dimitrijevic, M.
    Bozovic-Spasojevic, I.
    BREAST, 2021, 56 : S82 - S83
  • [36] Long-term survival in HER2-positive metastatic breast cancer: The first blow is half the battle
    Steenbruggen, T. G.
    van Ramshorst, M. S.
    Stouthard, J. M. L.
    Rodenhuis, S.
    Linn, S. C.
    Sonke, G. S.
    Smorenburg, C. H.
    CANCER RESEARCH, 2017, 77
  • [37] Real-world outcomes of long-term efficacy of T-DM1 after discontinuation due to limiting toxicity in patients with HER2-positive metastatic breast cancer
    Blotta, Daniella Audi
    Gomes, Jessica Ribeiro
    Rodrigues Moreira, Shermann Brandao
    Colosimo, Danielle Fortes
    Araujo, Julio
    Goncalves Ferreira, Carolina Cavalcanti
    Forgiarini, Elaine Aparecida
    Buzaid, Antonio C.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [38] Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry
    Lux, Michael P.
    Nabieva, Naiba
    Hartkopf, Andreas D.
    Huober, Jens
    Volz, Bernhard
    Taran, Florin-Andrei
    Overkamp, Friedrich
    Kolberg, Hans-Christian
    Hadji, Peyman
    Tesch, Hans
    Haeberle, Lothar
    Ettl, Johannes
    Lueftner, Diana
    Wallwiener, Markus
    Mueller, Volkmar
    Beckmann, Matthias W.
    Belleville, Erik
    Wimberger, Pauline
    Hielscher, Carsten
    Geberth, Matthias
    Abenhardt, Wolfgang
    Kurbacher, Christian
    Wuerstlein, Rachel
    Thomssen, Christoph
    Untch, Michael
    Fasching, Peter A.
    Janni, Wolfgang
    Fehm, Tanja N.
    Wallwiener, Diethelm
    Schneeweiss, Andreas
    Brucker, Sara Y.
    CANCERS, 2019, 11 (01):
  • [39] Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
    Denise A. Yardley
    Peter A. Kaufman
    Adam Brufsky
    Marianne Ulcickas Yood
    Hope Rugo
    Musa Mayer
    Cheng Quah
    Bongin Yoo
    Debu Tripathy
    Breast Cancer Research and Treatment, 2014, 145 : 725 - 734
  • [40] Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer
    Yardley, Denise A.
    Kaufman, Peter A.
    Brufsky, Adam
    Yood, Marianne Ulcickas
    Rugo, Hope
    Mayer, Musa
    Quah, Cheng
    Yoo, Bongin
    Tripathy, Debu
    BREAST CANCER RESEARCH AND TREATMENT, 2014, 145 (03) : 725 - 734
12345